...as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc....

...Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and...
...in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA...
...reimbursement. Bausch + Lomb, which acquired ISTA last June, said it will wind down the ISTA...

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. last year (see BioCentury, June 11, 2012). Ista...

...Bedminster, N.J. Business: Ophthalmic Appointed: Vicente Anido as chairman, formerly president and CEO of Ista Pharmaceuticals Inc....

...as CFO and EVP of corporate development, formerly VP of corporate development and CFO of Ista Pharmaceuticals Inc....

...Cancer, Antibodies Hired: Jane Henderson as SVP and CBO, formerly VP of business development at Ista Pharmaceuticals Inc....

...rights to bromfenac through its acquisition of Ista Pharmaceuticals Inc. earlier this month (see BioCentury, June 11). Ista...

...Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in...
...or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y. Ista Pharmaceuticals Inc....

...at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale. Last month, Ista...
...that Prolensa met the primary and secondary endpoints vs. placebo (see BioCentury, Oct. 17, 2011). Ista...
...acquired by Bausch + Lomb (see BioCentury, April 2). Croma-Pharma GmbH , Leobendorf, Austria Ista Pharmaceuticals Inc. (NASDAQ:ISTA...

...adverse events reported. Patients received twice-daily Beposone, bepotastine, a steroid or placebo for 2 weeks. Ista...
...from Mitsubishi, which markets bepotastine as Talion for allergic rhinitis and urticaria in Japan. Ista Pharmaceuticals Inc. (NASDAQ:ISTA...